AB
Therapeutic Areas
Amarin Corporation Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VASCEPA/VAZKEPA (Icosapent Ethyl) | Cardiovascular Risk Reduction | Approved |
| Icosapent Ethyl | CV Risk Reduction (Post-Myocardial Infarction) | Research |
Leadership Team at Amarin Corporation
PH
Patrick Holt
President and Chief Executive Officer
MW
Michael W. Kalb
Executive Vice President, Chief Legal Officer and Secretary
KM
Karim Mikhail
Executive Vice President and Chief Commercial Officer
SB
Steven B. Ketchum
Executive Vice President, President of R&D and Chief Scientific Officer